Zellweger spectrum disorders: clinical manifestations in patients surviving into adulthood

Authors: Kevin Berendse, Marc Engelen, Sacha Ferdinandusse, Charles B. L. M. Majoie, Hans R. Waterham, Frédéric M. Vaz, Johannes H. T. M. Koelman, Peter G. Barth, Ronald J. A. Wanders, Bwee Tien Poll-The

Affiliations: Department of Paediatric Neurology, Emma Children’s Hospital, Academic Medical Centre (AMC), University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands; Laboratory Genetic Metabolic Diseases, Emma Children’s Hospital, AMC, University of Amsterdam, Amsterdam, The Netherlands; Department of Radiology, AMC, University of Amsterdam, Amsterdam, The Netherlands; Department of Neurology and Clinical Neurophysiology, AMC, University of Amsterdam, Amsterdam, The Netherlands

License: © The Author(s) 2015 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Article links: DOI: 10.1007/s10545-015-9880-2  |  PubMed: 26287655  |  PMC: PMC4710674

Relevance: Moderate: mentioned 3+ times in text

Full text: PDF (2.9 MB)

Introduction

Zellweger spectrum disorders (ZSDs, OMIM #601539) constitute a subgroup of the peroxisome biogenesis disorders and represent a clinical continuum from severe to relatively milder phenotypes. ZSDs are caused by pathogenic mutations in at least 13 different PEX genes, encoding peroxins. Generally, there is genotype-phenotype correlation (Rosewich et al ref. 2005) (Moser ref. 1999). Patients with the severe phenotype present in the neonatal period with failure to thrive, jaundice, hypotonia and dysmorphic features (Weller et al ref. 2003) and high mortality within the first year of life. This severe phenotype was described as Zellweger syndrome (Bowen et al ref. 1964). Patients with a milder phenotype display a more variable symptomatology and age of presentation, but the onset is usually in early childhood. The most common presenting signs are developmental delay, with visual loss from retinal degeneration, sensorineural hearing loss and liver disease (Baumgartner et al ref. 1998). The majority of ZSD patients with a mild phenotype have normal MRI findings during childhood, but ultimately develop leukoencephalopathy later in life (Poll-The and Gärtner ref. 2012).

Definitive diagnosis requires laboratory investigations to assess peroxisomal functions, and confirmation by enzymatic analysis in fibroblasts, and/or PEX gene mutation studies.

Only limited data are available on the phenotype and natural history in adults with ZSDs (Rosewich et al ref. 2005) (Mignarri et al ref. 2012) (Matsui et al ref. 2013) (Raas-Rothschild et al ref. 2002) (Régal et al ref. 2010). To improve the accuracy of clinical diagnosis and to enable comparison of future evaluations of therapeutic interventions, we describe the natural history of a cohort of 19 patients (≥16 years) with molecularly defined ZSDs.

Material and methods

Patients

Retrospective clinical and laboratory data were collected from 19 ZSD patients. The diagnosis was confirmed by biochemical and molecular testing. Clinical and biochemical data were collected at many time points between 1991 and 2014. All patients were seen in the Academic Medical Centre in Amsterdam and examined by the authors (ME, PGB, or BTPT). Some data from patients 1, 3–6, 8, 13–14, 16–18 (Poll-The et al ref. 2004) and patient 4 (Ebberink et al ref. 2012) were reported previously. Age at diagnosis was defined as biochemically confirmed diagnosis, and not the onset of symptoms.

Hearing and visual assessment

Objective methods (brainstem audiometry evoked response and visually evoked potentials) and subjective methods (free-field audiometry and Snellen chart, with 1.0 scored as normal vision (Peters ref. 1961)) were used to asses hearing and visual impairment.

Imaging

A total of 39 MRI studies of the brain were performed in 16 patients. The studies were performed on a 1.5 T MR scanner using the following sequences: axial, sagittal and coronal spin-echo T1-weighted, T2-weighted and axial fluid-attenuated inversion recovery image. The first MRI scans of patients 8, 9, and 16–19, the first and second MRI’s of patients 1, 3, and 5 and the fourth MRI of patient 6 were described earlier (Barth et al ref. 2004). Liver cirrhosis was diagnosed using a Fibroscan, as described previously (Foucher et al ref. 2006).

Laboratory tests

To establish whether a patient is affected by a ZSD several peroxisomal metabolites, reflecting the in vivo function of peroxisomes, were determined in blood, including levels of VLCFA, phytanic and pristanic acid (Vreken et al ref. 1998), pipecolic acid (Rashed et al ref. 2001) and bile acids (Bootsma et al ref. 1999). In erythrocytes, plasmalogen (C16:0- and C18:0-dimethyl acetal) levels were measured (Dacremont and Vincent ref. 1995) and levels of oxalic acid and glycolic acids were determined in urine spots and corrected for creatinine excretion (Wolthers and Hayer ref. 1982). A total of 332 biochemical analyses were performed in plasma, ranging from two (patient 4) to 43 (patient 18) tests per patient. Adrenal insufficiency was diagnosed by means of an adrenocorticotropic hormone stimulation (Synacthen) test (Berendse et al ref. 2014).

Several peroxisomal parameters were studied in cultured skin fibroblasts including, catalase immunofluorescence microscopy (Wanders et al ref. 1989), VLCFA profile (Dacremont et al ref. 1995), peroxisomal alpha- and beta-oxidation activity (Wanders et al ref. 1995a) and dihydroxyacetonephosphate-acyltransferase (DHAPAT) activity (Wanders et al ref. 1995b).

Mutation analysis

Complementation analysis in cultured skin fibroblasts was used to determine the defective PEX gene, followed by Sanger sequencing on genomic DNA (Ebberink et al ref. 2011).

Statistical analysis

Mann–Whitney U tests were performed using the IBM Statistical package for the Social Sciences (SPSS) software version 20 (IBM, U.S.A.).

Standard protocol approvals, registrations and patient consents

For this project the IRB issued a waiver since the study is retrospective and only anonymized data was used. Written informed consent was obtained from the parents of all the patients, and authorization for disclosure of recognizable persons in photographs for publication were obtained.

Results

The detailed clinical characteristics of the 19 patients from 16 families are summarized in Tables 1 and 2. All patients, nine females and ten males, were of Caucasian background and no parental consanguinity was reported. To obtain a framework for comparing the severity of the neurologic disorder with the MRI findings and biochemical abnormalities we delineated two broad categories on the basis of the degree of communication. Patients in group 1 (patients 1–12) were able to communicate with structured grammatical speech and patients in group 2 (patients 13–19) had no structured speech. Age at diagnosis varied between 7 days and 31 years (mean group 1: 7.6 years, group 2: 1.2 years). The diagnosis of patients 3 and 16 was at an early age because they had an affected older sibling. In two other patients (2 and 4) there was a significant delay before diagnosis, due to normal peroxisomal metabolites in plasma and a clinical presentation atypical for a ZSD (Ebberink et al ref. 2012).

We obtained information about clinical features, biochemical profile, education, current level of social functioning and help required for activities of daily living.

Clinical features

During infancy, seven of the 19 patients had prolonged neonatal jaundice, four presented with hypotonia, five with failure to thrive, 12 had a visual handicap due to retinal degeneration and eight patients presented with hearing impairment (Table 1). During childhood, all patients had a moderate to severe developmental delay as well as visual and hearing loss. Current ages ranged from 16 to 35 years (mean 22.5 years). Patient 18 died from liver failure at 18 years. At last follow-up, all patients had nyctalopia and retinopathy, caused by retinitis pigmentosa in 16/19. Visual acuity ranged from 4 to 33 % (mean 14 %) with 100 % being normal vision and 5 % defined as legally blind in Europe (Kocur and Resnikoff ref. 2002). The visual impairment was progressive in four and stable in 14 patients. All had gross sensorineural hearing deficits, ranging from a loss of 60 dB to 110 dB and 17 patients (except patients 15 and 18) used hearing aids with clinical benefit. Ambulation ranged from running (11/19) to walking unsupported (3/19), walking with support (2/19) and the ability to sit unsupported (3/19). Patient 5 had normal motor function during childhood. However, since the age of 15 years he lost the ability to walk independently due to progressive cerebellar ataxia and weakness caused by peripheral neuropathy. At the age of 21 he developed pyramidal signs and became completely wheelchair-bound at 23 years. Patient 18 was able to walk independently at 4 years of age, but at the age of 14 years she developed progressive cerebellar and sensory ataxia and lost independent ambulation.

Specific findings included cerebellar signs in 9/19, pyramidal signs in 5/19 and signs of peripheral neuropathy in 11/19 patients (Table 2). The peripheral neuropathy could only be confirmed by nerve conduction studies in two patients (5 and 10), due to reluctance of the parents to allow latter studies. In these two patients the neuropathy was classified as a demyelinating neuropathy, according to established criteria with a motor conduction velocity below 41 ms in the median nerve and 35 ms in the peroneal nerve (Van Asseldonk et al ref. 2005). Overall, seven had progressive neurological symptoms (mainly worsening of the gait disorder) and 12 were stable at most recent follow-up. Epilepsy was not seen in any of the patients.

Non-neurological findings included splenomegaly, hepatomegaly, renal pelvic stones and adrenal insufficiency in one patient and liver cirrhosis in 3/19. All patients had enamel hypoplasia.

Activities of daily living

Of the 19 patients, six lived in assisted-care facilities (Table 1), of whom patients 15 and 17–18 lived in a round the clock care facility and were completely dependent on others (i.e., nursing home). The remaining three were self-supporting with respect to daily life activities, albeit under supervision. The other 13 patients lived with their parents, with or without continuous supervision. Of these patients, only patients 13 and 14 were not able to feed themselves independently. All patients except for patient 11 had a minor to severe gait disorder, limiting their physical mobility. Cognition varied widely from normal cognitive abilities in patient 11, to moderate or severe intellectual disability in most.

MRI findings

Cerebral MRI scans were available from 16 patients, with follow-up in 10 (Table 3). T2-weighted MR images showed progressive hyperintense white matter changes in the cerebral hemispheres in 4/16. These were located around the supratentorial ventricular system merging with surrounding normal white matter without sharp demarcation. Patient 6 (Fig. 1) had additional lesions in the corpus callosum and in the posterior limbs of the internal capsules. Follow-up images showed progressive central cerebellar white matter changes on T2-weighted images between 11 and 22 years. Furthermore, 8/16 patients had T2 hyperintensities in the areas surrounding the cerebellar dentate nuclei, which was progressive in 3 (patients 3, 5–6). T2-hyperintensity in the cerebellar white matter was seen in 6 patients, and was progressive in one (patient 6). Two patients (16, 18) had supratentorial ventricular dilatation and 6/16 presented with cerebellar cortical atrophy, of whom 3 patients (3, 16, 18) showed concomitant supratentorial cortical atrophy.

Laboratory tests

Detailed individual biochemical profiles, during the time of diagnosis and last follow-up, are described in Tables 4 and 5. At the last available measurement the most important abnormalities in plasma included elevated levels of C26:0 (16/19 patients), pipecolic acid (10/19 patients), DHCA (9/19 patients) and THCA (6/19 patients). There were two patients (patients 2 and 11) with only one mildly abnormal peroxisomal biomarker in plasma and erythrocytes. Compared with the biochemical results at time of diagnosis, we observed a decline in the levels of DHCA and THCA (15/19 patients), C29-dicarboxylic acid (13/14 patients) and pipecolic acid (10/19 patients), and in some patients even a complete normalization (patients 6–11, 14, 19).

In general, patients had reduced levels of fat soluble vitamins (A, D, E and K) and a coagulopathy, due to a combined vitamin K malabsorption and liver dysfunction. The majority of patients had a low-phytanic acid and low-fat diet and 14 patients received vitamin A, D, E and K supplementation.

Discussion

The ZSDs have long been considered lethal in infancy or early childhood, based on the original description of Zellweger syndrome (Bowen et al ref. 1964). In this retrospective study, we describe a large cohort of patients with a ZSD and show that the natural history is highly variable with a distinct subgroup surviving well into adulthood. The phenotypic spectrum is therefore much wider, with implications for counseling of patients and their families.

We attempted to identify clinical, biochemical, genetic and/or MRI characteristics typical for this subgroup with long survival. We divided the patients in this cohort into two categories based on the degree of communication. Patients in group 1 (patients 1–12) were able to communicate with structured grammatical speech and patients in group 2 (patients 13–19) did not achieve structured speech. The correlation between the phenotype and genotype, at least with respect to the mild PEX1 c.2528G>A and PEX26 c.292C>T mutation in its homozygous form versus the more severe compound heterozygosity (PEX1 c.2097insT+PEX1 c.2528G > A), which was described previously (Rosewich et al ref. 2005) (Bader et al ref. 2000), was also seen in our study.

In previous case reports, age at first symptoms varied from 3 to 12 years and age at diagnosis varied from 10 to 51 years (Rosewich et al ref. 2005) (Mignarri et al ref. 2012) (Matsui et al ref. 2013) (Raas-Rothschild et al ref. 2002) (Régal et al ref. 2010). The average age at diagnosis in our cohort was at a much earlier age of 5.2 years. Hence, we had the possibility to monitor the clinical and biochemical spectrum over a relatively long period of time.

Hearing impairment, an important characteristic of ZSD patients (Moser et al ref. 1995), was not reported in some of the mild adult patients described in previous reports (Régal et al ref. 2010) (Sevin et al ref. 2011) (Steinberg et al ref. 2009), but all patients in our cohort had impaired hearing and vision. The predominant neurological symptom in the adult patients is a gait disorder, caused by combinations of a cerebellar syndrome, pyramidal tract dysfunction and peripheral neuropathy. Unexpectedly, we observed a high prevalence of signs of peripheral neuropathy in adolescence/adulthood (11/19), especially in group 2 (6/7), while none of these patients presented these symptoms in childhood. The majority of patients was diagnosed with a peripheral neuropathy on clinical grounds. Confirmatory nerve conduction studies, however, were only performed in two patients, which is a limitation of our study. As reported previously (England et al ref. 2005), the combination of signs and symptoms have a relatively good accuracy for diagnosing a peripheral neuropathy. It is noteworthy that two patients developed a demyelinating peripheral neuropathy. This contrasts with another peroxisomal disease, X-linked adrenoleukodystrophy, in which axonal rather than a demyelinating peripheral neuropathy is usually present (van Geel et al ref. 1996) (Engelen et al ref. 2011) (Chaudhry et al ref. 1996).

Previous MRI studies showed progressive cerebral demyelination in peroxisome biogenesis disorder patients with a mild phenotype, mostly in the cerebellum, brainstem, posterior limb of the internal capsule and posterior cerebral white matter (Barth et al ref. 2004). In this study, the major MRI abnormalities (i.e., white matter hyperintensities) were found in the central white matter of both cerebellar hemispheres and/or areas surrounding the dentate nuclei on T2-weighted images (9/16). These lesions can also be found in patients with D-bifunctional protein deficiency, an isolated peroxisomal β-oxidation defect, with prolonged survival (i.e., >7.5 years) (Ferdinandusse et al ref. 2006). Normal MRI was found in five patients. Symptomatic leukoencephalopathy was present in seven patients (2, 5–6, 9, 12, 17–18) and silent leukoencephalopathy in two (3, 8). Overall, individuals in both groups presented similar findings on MRI ranging from normal findings to leukoencephalopathy.

Liver dysfunction is a common feature in ZSD patients. However, in this cohort only four patients (in group 2) had liver cirrhosis/fibrosis. The prevalence of hyperoxaluria (2/14) and hyperglycolic aciduria (3/13) was much lower than previously reported in ZSD patients older than 1 year (van Woerden et al ref. 2006). Only patient 18 suffered from nephro- and urolithiasis.

In our cohort 12 patients were clinically stable in recent years and seven showed a progressive disease course. The disease progression becomes apparent in adolescence (age 12–16 years), with gait disturbance being the most prominent symptom (in 7/7).

Seventeen of the 19 patients had a typical ZSD biochemical phenotype in blood at the time at diagnosis. At latest follow-up we observed normal blood levels of several peroxisomal biomarkers in patients (Table 4). Normal levels of some parameters have already been reported by others (Sevin et al ref. 2011) (Ebberink et al ref. 2010). Importantly, our study is the first to show a decline in the levels of these metabolites with age and in some patients even a complete normalization. In particular the levels of DHCA, THCA, and pipecolic acid were found to decline during life and they eventually normalized. In some patients we noted a decrease in these parameters as well as in liver enzymes. This suggests that improved liver function might play a role in the decrease of these metabolites, as they are predominantly synthesized in the liver (Ferdinandusse and Houten ref. 2006). However, there were also patients with normal liver function and elevated levels of abnormal peroxisomal metabolites in childhood. In these patients we also observed a decline in these peroxisomal parameters, meaning that this decline cannot be entirely attributed to normalization of liver functions. The decline in DHCA and THCA levels may also be caused by a decreased synthesis of bile acids with increasing age (Einarsson et al ref. 1985). Furthermore, we observed strong fluctuation of several parameters in the majority of the patients. The concentration of peroxisomal metabolites can fluctuate between normal and abnormal (Fig. 1). Overall, the diagnosis ZSD would be missed in two patients (2 and 11) at last follow-up and in patient 4 at first analysis based on the C26:0, bile acid levels, pristanic- and phytanic acid concentrations in plasma.

Our data suggest that a ZSD cannot be excluded by biochemical testing in plasma alone, and that in some individuals (i.e., patient 2, 4, and 11) a complete analysis in skin fibroblasts (including culturing fibroblasts at 40 °C (Ebberink et al ref. 2012)) is indicated if clinical suspicion is high. Skin fibroblast examination is also necessary to discriminate between a ZSD or a single-enzyme deficiency, which is diagnosed in at least 15 % of the individuals presenting with a ZSD clinical phenotype (Steinberg et al ref. 2003). Recently, D-bifunctional protein-deficiency has been identified by whole-exome sequencing in seven adults without detectable biochemical abnormalities in blood (Pierce et al ref. 2010) (McMillan et al ref. 2012) (Lines et al ref. 2014). Because of considerable overlap between Usher syndrome and milder ZSD phenotypes, i.e., the combination of deafness and retinitis pigmentosa, individuals suspected to have Usher syndrome should be screened for peroxisomal dysfunction (Raas-Rothschild et al ref. 2002).

Efforts to correlate biochemical, cellular, and molecular characteristics of ZSD patients to their clinical outcome, mainly in terms of survival, have provided valuable information. Gootjes et al suggested that DHAPAT and C26:0 β-oxidation activity are predictors of survival in patients with a ZSD. However, these measurements in cultured skin fibroblasts could only be used to roughly predict survival of <1 year or >5 years (Gootjes et al ref. 2002). Despite these associations, prediction of prognosis remains challenging and is influenced by many other variables (e.g., quality of supportive care). We evaluated how the parameters of peroxisomal dysfunction relate to disease severity and long-term progression. We noticed higher levels of abnormal peroxisomal metabolites (e.g., DHCA, THCA, and C26:0) in group 2 during childhood, but there were no differences in adulthood. Concentrations of pipecolic acid were higher in those patients with a progressive disease course. Patients in group 2 had higher levels of C26:0 in plasma than patients in group 1 throughout life (Fig. 1d). Ferdinandusse et al reported that C27-bile acid intermediates (DHCA/THCA) induce apoptosis, decrease cell viability and are more toxic than C24-bile acids (Ferdinandusse et al ref. 2009). It is noteworthy that the most severely affected patient (18) had extremely high plasma levels of DHCA and THCA ranging from 50 to 130 μmol/l in the first year of life. The patients with a less severe phenotype presented with DHCA and THCA levels of approximately 10 and 2 μmol/l, respectively. However, on the basis of the present study, we were unable to identify a correlation between the concentration of abnormal peroxisomal metabolites, skin fibroblast data and the severity of the clinical phenotype or progression of the disease. The metabolites measured in plasma probably do not reflect the level of accumulation in organs. This suggests that the wide spectrum of clinical presentations may be related to varying amounts of residual peroxisomal enzymatic activities in target tissue. Further studies are therefore required to determine the precise role of the peroxisomal biomarkers in the pathogenesis of ZSDs. The recently constructed PEX1 mouse model (Hiebler et al ref. 2014) may be a valid model to study these relations.

In summary, we describe the natural history of a cohort of ZSD patients who reached adulthood and represent a distinct subgroup within the ZSDs. A high percentage of patients show pyramidal symptoms with or without peripheral neuropathy. Some patients with prolonged survival present an insidiously progressive disease course, despite normalization of biomarkers for peroxisomal disease measured in plasma and erythrocytes. This study emphasizes that ZSDs should no longer be considered solely as a paediatric disease, but rather as a slowly progressive disease with patients surviving into adulthood. This study is important for the interpretation of future therapeutic trials and for those involved in the clinical care of adult patients.

References

1. PI Bader, S Dougherty, N Cangany. Infantile Refsum disease in four Amish sibs. Am J Med Genet, 2000. [DOI | PubMed]
2. PG Barth, CBLM Majoie, J Gootjes. Neuroimaging of peroxisome biogenesis disorders (Zellweger spectrum) with prolonged survival. Neurology, 2004. [DOI | PubMed]
3. MR Baumgartner, BT Poll-The, NM Verhoeven. Clinical approach to inherited peroxisomal disorders: a series of 27 patients. Ann Neurol, 1998. [DOI | PubMed]
4. K Berendse, M Engelen, GE Linthorst. High prevalence of primary adrenal insufficiency in Zellweger spectrum disorders. Orphanet J Rare Dis, 2014. [DOI | PubMed]
5. AH Bootsma, H Overmars, A van Rooij. Rapid analysis of conjugated bile acids in plasma using electrospray tandem mass spectrometry: application for selective screening of peroxisomal disorders. J Inherit Metab Dis, 1999. [DOI | PubMed]
6. P Bowen, CS Lee, H Zellweger, R Lindenberg. A familial syndrome of multiple congenital defects. Bull Johns Hopkins Hosp, 1964. [PubMed]
7. V Chaudhry, HW Moser, DR Cornblath. Nerve conduction studies in adrenomyeloneuropathy. J Neurol Neurosurg Psychiatry, 1996. [DOI | PubMed]
8. G Dacremont, G Vincent. Assay of plasmalogens and polyunsaturated fatty acids (PUFA) in erythrocytes and fibroblasts. J Inherit Metab Dis, 1995. [DOI | PubMed]
9. G Dacremont, G Cocquyt, G Vincent. Measurement of very long-chain fatty acids, phytanic and pristanic acid in plasma and cultured fibroblasts by gas chromatography. J Inherit Metab Dis, 1995. [DOI | PubMed]
10. MS Ebberink, B Csanyi, WK Chong. Identification of an unusual variant peroxisome biogenesis disorder caused by mutations in the PEX16 gene. J Med Genet, 2010. [DOI | PubMed]
11. MS Ebberink, PAW Mooijer, J Gootjes. Genetic classification and mutational spectrum of more than 600 patients with a Zellweger syndrome spectrum disorder. Hum Mutat, 2011. [DOI | PubMed]
12. MS Ebberink, J Koster, G Visser. A novel defect of peroxisome division due to a homozygous non-sense mutation in the PEX11β gene. J Med Genet, 2012. [DOI | PubMed]
13. K Einarsson, K Nilsell, B Leijd, B Angelin. Influence of age on secretion of cholesterol and synthesis of bile acids by the liver. N Engl J Med, 1985. [DOI | PubMed]
14. M Engelen, AJ van der Kooi, S Kemp. X-linked adrenomyeloneuropathy due to a novel missense mutation in the ABCD1 start codon presenting as demyelinating neuropathy. J Peripher Nerv Syst, 2011. [DOI | PubMed]
15. JD England, GS Gronseth, G Franklin. Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology, 2005. [DOI | PubMed]
16. S Ferdinandusse, SM Houten. Peroxisomes and bile acid biosynthesis. Biochim Biophys Acta, 2006. [DOI | PubMed]
17. S Ferdinandusse, S Denis, PAW Mooyer. Clinical and biochemical spectrum of D-bifunctional protein deficiency. Ann Neurol, 2006. [DOI | PubMed]
18. S Ferdinandusse, S Denis, G Dacremont, RJA Wanders. Toxicity of peroxisomal C27-bile acid intermediates. Mol Genet Metab, 2009. [DOI | PubMed]
19. J Foucher, E Chanteloup, J Vergniol. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut, 2006. [DOI | PubMed]
20. J Gootjes, PAW Mooijer, C Dekker. Biochemical markers predicting survival in peroxisome biogenesis disorders. Neurology, 2002. [DOI | PubMed]
21. S Hiebler, T Masuda, JG Hacia. The Pex1-G844D mouse: a model for mild human Zellweger spectrum disorder. Mol Genet Metab, 2014. [DOI | PubMed]
22. I Kocur, S Resnikoff. Visual impairment and blindness in Europe and their prevention. Br J Ophthalmol, 2002. [DOI | PubMed]
23. MA Lines, R Jobling, L Brady. Peroxisomal D-bifunctional protein deficiency: three adults diagnosed by whole-exome sequencing. Neurology, 2014. [DOI | PubMed]
24. S Matsui, M Funahashi, A Honda, N Shimozawa. Newly identified milder phenotype of peroxisome biogenesis disorder caused by mutated PEX3 gene. Brain Dev, 2013. [DOI | PubMed]
25. HJ McMillan, T Worthylake, J Schwartzentruber. Specific combination of compound heterozygous mutations in 17β-hydroxysteroid dehydrogenase type 4 (HSD17B4) defines a new subtype of D-bifunctional protein deficiency. Orphanet J Rare Dis, 2012. [DOI | PubMed]
26. A Mignarri, C Vinciguerra, A Giorgio. Zellweger spectrum disorder with mild phenotype caused by PEX2 gene mutations. JIMD Rep, 2012. [DOI | PubMed]
27. HW Moser. Genotype-phenotype correlations in disorders of peroxisome biogenesis. Mol Genet Metab, 1999. [DOI | PubMed]
28. AB Moser, M Rasmussen, S Naidu. Phenotype of patients with peroxisomal disorders subdivided into sixteen complementation groups. J Pediatr, 1995. [DOI | PubMed]
29. HB Peters. Vision screening with a Snellen chart. Am J Optom Arch Am Acad Optom, 1961. [DOI | PubMed]
30. SB Pierce, T Walsh, KM Chisholm. Mutations in the DBP-deficiency protein HSD17B4 cause ovarian dysgenesis, hearing loss, and ataxia of Perrault Syndrome. Am J Hum Genet, 2010. [DOI | PubMed]
31. BT Poll-The, J Gärtner. Clinical diagnosis, biochemical findings and MRI spectrum of peroxisomal disorders. Biochim Biophys Acta, 2012. [DOI | PubMed]
32. BT Poll-The, J Gootjes, M Duran. Peroxisome biogenesis disorders with prolonged survival: phenotypic expression in a cohort of 31 patients. Am J Med Genet A, 2004. [DOI | PubMed]
33. A Raas-Rothschild, RJA Wanders, PAW Mooijer. A PEX6-defective peroxisomal biogenesis disorder with severe phenotype in an infant, versus mild phenotype resembling Usher syndrome in the affected parents. Am J Hum Genet, 2002. [DOI | PubMed]
34. MS Rashed, LY Al-Ahaidib, HY Aboul-Enein. Determination of L-pipecolic acid in plasma using chiral liquid chromatography-electrospray tandem mass spectrometry. Clin Chem, 2001. [PubMed]
35. L Régal, MS Ebberink, N Goemans. Mutations in PEX10 are a cause of autosomal recessive ataxia. Ann Neurol, 2010. [PubMed]
36. H Rosewich, A Ohlenbusch, J Gärtner. Genetic and clinical aspects of Zellweger spectrum patients with PEX1 mutations. J Med Genet, 2005. [DOI | PubMed]
37. C Sevin, S Ferdinandusse, HR Waterham. Autosomal recessive cerebellar ataxia caused by mutations in the PEX2 gene. Orphanet J Rare Dis, 2011. [DOI | PubMed]
38. Steinberg SJ, Raymond GV, Braverman NE, et al (2003) Peroxisome biogenesis disorders, Zellweger syndrome spectrum. In: GeneReviews Medical Genetics Information Resource [online]. Available at: http://www.ncbi.nlm.nih.gov/books/NBK1448/. Accessed 12 Dec
39. SJ Steinberg, A Snowden, NE Braverman. A PEX10 defect in a patient with no detectable defect in peroxisome assembly or metabolism in cultured fibroblasts. J Inherit Metab Dis, 2009. [DOI | PubMed]
40. JTH Van Asseldonk, LH Van Den Berg, S Kalmijn. Criteria for demyelination based on the maximum slowing due to axonal degeneration, determined after warming in water at 37°C: Diagnostic yield in chronic inflammatory demyelinating polyneuropathy. Brain, 2005. [DOI | PubMed]
41. BM Van Geel, JHTM Koelman, PG Barth, BW Ongerboer de Visser. Peripheral nerve abnormalities in adrenomyeloneuropathy: a clinical and electrodiagnostic study. Neurology, 1996. [DOI | PubMed]
42. CS Van Woerden, JW Groothoff, FA Wijburg. High incidence of hyperoxaluria in generalized peroxisomal disorders. Mol Genet Metab, 2006. [DOI | PubMed]
43. P Vreken, AE van Lint, A Bootsma. Rapid stable isotope dilution analysis of very-long-chain fatty acids, pristanic acid and phytanic acid using gas chromatography–electron impact mass spectrometry. J Chromatogr B Biomed Sci Appl, 1998. [DOI | PubMed]
44. RJA Wanders, EA Wiemer, S Brul. Prenatal diagnosis of Zellweger syndrome by direct visualization of peroxisomes in chorionic villus fibroblasts by immunofluorescence microscopy. J Inherit Metab Dis, 1989. [PubMed]
45. RJA Wanders, S Denis, JP Ruiter. Measurement of peroxisomal fatty acid beta-oxidation in cultured human skin fibroblasts. J Inherit Metab Dis, 1995. [DOI | PubMed]
46. Wanders RJA, Ofman R, Romeijn GJ, Schutgens RBH (1995b) Measurement of dihydroxyacetone-phosphate acyltransferase (DHAPAT) in chorionic villous samples, blood cells and cultured cells. J Inherit Metab Dis 1:90–100
47. S Weller, SJ Gould, D Valle. Peroxisome biogenesis disorders. Annu Rev Genomics Hum Genet, 2003. [DOI | PubMed]
48. BG Wolthers, M Hayer. The determination of oxalic acid in plasma and urine by means of capillary gas chromatography. Clin Chim Acta, 1982. [DOI | PubMed]